Hsieh, Y.-P.; Wang, Y.-J.; Feng, L.-Y.; Wu, L.-T.; Li, J.-H.
Mifepristone (RU-486®) as a Schedule IV Controlled Drug—Implications for a Misleading Drug Policy on Women’s Health Care. Int. J. Environ. Res. Public Health 2022, 19, 8363.
https://doi.org/10.3390/ijerph19148363
AMA Style
Hsieh Y-P, Wang Y-J, Feng L-Y, Wu L-T, Li J-H.
Mifepristone (RU-486®) as a Schedule IV Controlled Drug—Implications for a Misleading Drug Policy on Women’s Health Care. International Journal of Environmental Research and Public Health. 2022; 19(14):8363.
https://doi.org/10.3390/ijerph19148363
Chicago/Turabian Style
Hsieh, Yi-Ping, Yun-Ju Wang, Ling-Yi Feng, Li-Tzy Wu, and Jih-Heng Li.
2022. "Mifepristone (RU-486®) as a Schedule IV Controlled Drug—Implications for a Misleading Drug Policy on Women’s Health Care" International Journal of Environmental Research and Public Health 19, no. 14: 8363.
https://doi.org/10.3390/ijerph19148363
APA Style
Hsieh, Y.-P., Wang, Y.-J., Feng, L.-Y., Wu, L.-T., & Li, J.-H.
(2022). Mifepristone (RU-486®) as a Schedule IV Controlled Drug—Implications for a Misleading Drug Policy on Women’s Health Care. International Journal of Environmental Research and Public Health, 19(14), 8363.
https://doi.org/10.3390/ijerph19148363